Summit Therapeutics' Partner Akeso Announces Overall Survival Results From The Randomized, Double-Blind Phase III HARMONi-2 Study Evaluating Ivonescimab Monotherapy; Ivonescimab Monotherapy Demonstrated A Statistically Significant Improvement Compared To Pembrolizumab Monotherapy.
Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab
Summit's medicine partner shared good news: their new drug ivonescimab helped people live longer than an older medicine did. When a medicine passes an important test like this, it's a sign the company might be moving forward with something valuable.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.